- New investigational tazemetostat combination data in relapsed/refractory follicular lymphoma selected for oral presentation at ASH 2022
- An established leader in difficult-to-treat cancer types expands oncology focus into hematology with acquisition of Epizyme
November 3, 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) will highlight its expanded portfolio in hematology at the American Society of Hematology (ASH) Annual Meeting from December 10-13 following its recent acquisition of Epizyme. The company will share an oral presentation on new interim data from a Phase 1b/3 trial of investigational tazemetostat, an oral EZH2 inhibitor, as a second-line combination regimen for relapsed/refractory follicular lymphoma (FL).
“As a company, we have long pursued solutions for some of the most difficult-to-treat cancer types, including pancreatic cancer and neuroendocrine tumors. Our recent portfolio expansion further delivers on our promise and also builds our scientific expertise in epigenetics,” said Mónica de Abadal, Senior Vice President of North America Medical Affairs at Ipsen. “We’re excited to showcase early results from the ongoing combination data in relapsed/refractory follicular lymphoma at ASH.”
New interim results from SYMPHONY-1 combination study
In an oral presentation at ASH, new interim data from the safety run-in of the Phase 1b/3 SYMPHONY-1 study will be presented, including response data, duration of response, and progression-free survival data, as well as safety data. The SYMPHONY-1 trial is an international, multicenter, randomized, double-blind, active-controlled, three-stage study evaluating the safety and efficacy of investigational tazemetostat in combination with lenalidomide and rituximab for second-line treatment of relapsed/refractory FL.
Monday, December 12 at 5:45 p.m. ET (R06-R09) Session #623: Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Lymphoma: Phase 1b/3 Results of SYMPHONY-1
Follicular lymphoma is a cancer of the lymphatic system and a type of non-Hodgkin lymphoma (NHL) that develops when the body makes abnormal B lymphocytes. These lymphocytes are a type of white blood cell that normally helps fight infections. In FL, the lymphocytes slowly build up in the lymph nodes or other body organs. Each year, approximately 20,000 people in the U.S. are diagnosed with FL and most are diagnosed with advanced disease, as it can be difficult to detect.
Epigenetics, an emerging frontier in cancer treatment
The acquisition of Epizyme includes an epigenetic platform, which is an innovative approach to developing investigational cancer medicines that focuses on identifying and targeting key targets that alter or dysregulate the basic structural components of chromosomes in DNA–called chromatin–to slow or stop tumor cell proliferation.
ENDS
About Ipsen
Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. With Specialty Care sales of €2.6bn in FY 2021, Ipsen sells medicines in over 100 countries. Alongside its external-innovation strategy, the Company’s research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen, excluding its Consumer HealthCare business, has around 4,500 colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com
Ipsen’s Forward-Looking Statements
The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words ‘believes’, ‘anticipates’ and ‘expects’ and similar expressions are intended to identify forward-looking statements, including Ipsen’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen’s patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen’s activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen’s partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen’s business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen’s 2021 Universal Registration Document, available on ipsen.com
|
For further information:
|
